A 28-residue peptide corresponding to the entire amino acid sequence of vasoactive intestinal polypeptide of guinea pig origin (gVIP) was synthesized by assembling 6 peptide fragments, followed by thioanisole-mediated deprotection with 1 M trimethylsilyl trifluoromethanesulfonate in trifluoroacetic acid. The synthetic peptide was biologically as active as synthetic porcine VIP, but behaved immunologically in a different manner from the above mammalian VIP.
Mammalian vasoactive intestinal polypeptide (VIP) has been reported to have an identical amino acid sequence in four species, i.e., pig,3) cow,4) human5) and rat.6) However, guinea pig VIP (gVIP) sequenced by Du et al.,7) was found to differ from other mammalian VIP's by four amino acid substitutions at positions 5, 9, 19, and 26. In order toevaluate its biological and immunological properties, we undertook the solution phase synthesis of this unique mammalian VIP, according to the route illustrated in Fig. 1 .
Different from our previous synthesis of porcine VIP,81 our newly found thioanisolemediated deprotecting procedure9) with TMSOTf/TFA was applied in the final step of the present synthesis. The peptide chain was constructed by assembling six fragments.Of these, two fragments, [31 and [4] , are those employed for the previous porcine VIP synthesis. Like porcine VIP, gVIP possesses two Asp residues sensitive to base-catalyzed cyclization.10) In order to suppress this type of side reaction, Asp(OChp)11) was employed. In addition, in order to exclude the possibility of over-acylation during fragment condensation, a masked Tyr derivative, Tyr(C12-Bz1),12) was employed.
The C-terminal fragment [1] , Boc-Tyr(C12-Bz1)-Leu-Asn-Ser(Bz1)-Val-Leu-Asn-NH2, was prepared by azide condensation'13) of two tripeptide units, Z(OMe)-Val-Leu-Asn-NH2 and Z(OMe)-Leu-Asn-Ser(Bzl)-NHNH2, followed by Su condensation14) of Boc-Tyr(C12-Bz1)-OH as shown in Fig. 2 . The former unit was prepared by azide condensation of Z(OMe)-Val-Leu-NHNH215) with a TFA-treated sample of Z(OMe)-Asn-NH2 and the latter unit by Np condensation of the respective amino acids in a stepwise manner.
For preparation of fragment [2] , Z(OMe)-Ala-Met(O)-Lys(Z)-Lys(Z)-NHNH2, the known dipeptide, Z(OMe)-Ala-Met-OMe16) was first converted to Z(OMe)-Ala-Met(O)-NHNH2 by NaIO, oxidation, followed by usual hydrazine treatment. This hydrazide was then condensed with a TFA-treated sample of Z(OMe)-Lys(Z)-Lys(Z)-OMe17) via the azide to give the protected tetrapeptide ester, which was smoothly converted to [2] by hydrazine treatment.
Fragment [5] , Z(OMe)-Thr-Asp(OChp)-Thr-Tyr(C12-Bz1)-NHNH2, was prepared with the aid of substituted hydrazine, Troc-NHNH2.18) Starting with Boc-Tyr(C12-Bz1)-NHNHTroc prepared by the mixed anhydride procedure,19) Z(OMe)-Thr-Asp(OChp)-ThrTyr(C12-Bz1)-NHNH-Troc was prepared in a stepwise manner as shown in Fig. 3 . From this tetrapeptide derivative, the Troc group was removed by treatment with Zn powder in AcOH-DMF to give [5] .
The N-terminal fragment, Z(OMe)-His-Ser(Bzl)-Asp(OChp)-Ala-Leu-Phe-NHNH2 [6] , was also prepared with the aid of Troc-NHNH2 as shown in Fig. 4 . A TFA-treated sample of Z(OMe)-Phe-NHNH-Troc20) was condensed with Z(OMe)-Ala-Leu-NHNH2, derived from the corresponding Me ester. 21 The resulting tripeptide chain was elongated by successive condensations of Z(OMe)-Asp(OChp)-OH via the Su ester and Z(OMe)-HisSer(Bz1)-NHNH222) via the azide. From the resulting hexapeptide derivative, the Troc group was removed by Zn treatment as stated above to give [6] .
Six fragments thus obtained were successively condensed by the azide procedure according to the route shown in Fig. 1 . Every reaction was carried out in a mixture of DMF and DMSO and the amount of the acyl component was increased from 1.5 to 3 equivalents as (20 ml) and TEA (1.3 ml, 1.2 eq) were added to an ice-chilled solution of a TFAtreated sample of Boc-Tyr(Cl2-Bzl)-NHNH-Troc (5.00 g, 7.94 mmol) in DMF (50 ml) containing TEA (1.1 ml, 1 eq) and the mixture was stirred for 18 h. The product was purified by procedure A, followed by precipitation from DMF with ether; yield 4.79 g (76%), Rf1, 0.71. Physical constants and analytical data are listed in Table III , together with those of protected peptides related to fragments [5] and [6] .
Z(OMe)-Asp(OChp)-Thr-Tyr(Cl2-Bzl)-NHNH-Troc (Positions 8-10)-Z(OMe)-Asp(OChp)-OSu [prepared from 3.72 g (1.5 eq) of the CHA salt as usual] in THF (30 ml) and NMM (0.83 ml, 1.5 eq) were added to a solution of a TFA-treated sample of the above dipeptide derivative (4.00 g, 5.03 mmol) in DMF (40 ml) containing TEA (0.55 ml, 1 eq), and the mixture was stirred at 4 °C for 18 h. The product was purified by procedure A, followed by precipitation from DMF with a mixture of MeOH and ether; yield 2.84 g (56%), Rf2 0. 
